The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

被引：201

作者：

Giles, Francis J. ^{[1
]}

Borthakur, Gautam ^{[1
]}

Ravandi, Farhad ^{[1
]}

Faderl, Stefan ^{[1
]}

Verstovsek, Srdan ^{[1
]}

Thomas, Deborah ^{[1
]}

Wierda, William ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

Kornblau, Steven ^{[1
]}

Pierce, Sherry ^{[1
]}

Albitar, Maher ^{[1
]}

Cortes, Jorge ^{[1
]}

Kantarjian, Hagop ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2007年 / 136卷 / 04期

关键词：

acute myeloid leukaemia; induction chemotherapy; comorbidity; prognosis;

D O I：

10.1111/j.1365-2141.2006.06476.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy. HCTCI score was 0 in 22% of patients, 1-2 in 30%, and >= 3 in 48%. In patients with scores of 0, 1-2, or >= 3, early death rates were 3%, 11% and 29% (P < 0.001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.

引用

页码：624 / 627

页数：4

共 12 条

[1] Age and acute myeloid leukemia [J].

Appelbaum, FR ;

Gundacker, H ;

Head, DR ;

Slovak, ML ;

Willman, CL ;

Godwin, JE ;

Anderson, JE ;

Petersdorf, SH .

BLOOD, 2006, 107 (09) :3481-3485

[2] Treatment of older patients with acute myeloid leukemia - New agents [J].

Burnett, AK ;

Mohite, U .

SEMINARS IN HEMATOLOGY, 2006, 43 (02) :96-106

[3] VALIDATION OF A COMBINED COMORBIDITY INDEX [J].

CHARLSON, M ;

SZATROWSKI, TP ;

PETERSON, J ;

GOLD, J .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) :1245-1251

[4] Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B [J].

Froehling, Stefan ;

Schlenk, Richard F. ;

Kayser, Sabine ;

Morhardt, Martina ;

Benner, Axel ;

Doehner, Konstanze ;

Doehner, Hartmut .

BLOOD, 2006, 108 (10) :3280-3288

[5] Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia [J].

Giles, Francis ;

Rizzieri, David ;

Karp, Judith ;

Vey, Norbert ;

Ravandi, Farhad ;

Faderl, Stefan ;

Khan, Khuda Dad ;

Verhoef, Gregor ;

Wijermans, Pierre ;

Advani, Anjali ;

Roboz, Gail ;

Kantarjian, Hagop ;

Bilgrami, Syed Fazl Ali ;

Ferrant, Augustin ;

Daenen, Simon M. G. J. ;

Karsten, Verena ;

Cahill, Ann ;

Albitar, Maher ;

Mufti, Ghulam ;

O'Brien, Susan .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :25-31

[6] Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy [J].

Gupta, V ;

Chun, K ;

Yi, QL ;

Minden, M ;

Schuh, A ;

Wells, R ;

Brandwein, J .

CANCER, 2005, 103 (10) :2082-2090

[7] Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival [J].

Juliusson, G ;

Billström, R ;

Gruber, A ;

Hellström-Linderg, E ;

Höglund, M ;

Karlsson, K ;

Stockelberg, D ;

Wahlin, A ;

Åström, M ;

Arnesson, C ;

Brunell-Abrahamsson, U ;

Carstensen, J ;

Fredriksson, E ;

Holmberg, E ;

Nordenskjöld, K ;

Wiklund, F .

LEUKEMIA, 2006, 20 (01) :42-47

[8] Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome [J].

Kantarjian, H ;

O'Brien, S ;

Cortes, J ;

Giles, F ;

Faderl, S ;

Jabbour, E ;

Garcia-Manero, G ;

Wierda, W ;

Pierce, S ;

Shan, JQ ;

Estey, E .

CANCER, 2006, 106 (05) :1090-1098

[9] Trends in the treatment of acute myeloid leukaemia in the elderly [J].

Lang, K ;

Earle, CC ;

Foster, T ;

Dixon, D ;

Van Gool, R ;

Menzin, J .

DRUGS & AGING, 2005, 22 (11) :943-955

[10] The outcomes and costs of acute myeloid leukemia among the elderly [J].

Menzin, J ;

Lang, K ;

Earle, CC ;

Kerney, D ;

Mallick, R .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (14) :1597-1603

← 1 2 →